Hemispherx BioPharma Inc.

AMEX: HEBHealthcare / Biotechnology / USA
1.9200.00Vol 35 4121Y Perf -83.53%
Aug 21st, 2019 14:51
BID1.91 ASK1.96
Open1.92 Previous Close1.92
Pre-Market- After-Trading-
 - -%  - -%
Target Price
8.00 
Analyst Rating
Strong Buy 1.00
Potencial %
316.67 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
100/100/100 
Growth Ranking
★★     44.18
Insiders Shares Cnt. % 3/6/12M
100/100/100 
Income Ranking
 —    -
Market Cap (mil)4 
Earnings Rating
Buy
Price Range Ratio 52wk %
1.75 
Earnings Date
21st Aug 2019

Today's Price Range

1.791.98

52wk Range

1.6914.81

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
1.05%
1 Month
-38.66%
3 Months
1 376.92%
6 Months
860.00%
1 Year
-83.53%
3 Years
-5.88%
5 Years
611.11%
10 Years
1.05%

Name / TickerPriceChg.Chg.%
HEB1.920.00000.00
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q04 2016--0.04-
Q02 2016--0.01-
Q01 2016--0.01-
Q04 2015--0.01-
Q03 2015--0.02-
Q02 2015--0.02-
Q01 2015--0.02-
Q04 2014--0.02-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume35 412
Shares Outstanding (in ths.)2 307
Trades Count425
Dollar Volume345 501
Avg. Volume105 754
Avg. Weekly Volume58 077
Avg. Monthly Volume130 399
Avg. Quarterly Volume175 614
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
RatingStrong Buy
1.00
Strong Buy
1.00
-

Hemispherx BioPharma Inc.

Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.

CEO: Thomas K. Equels

Teplephone: +1 215 988-0080

Address: 2117 SW Highway 484, Ocala 34473, FL, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

74%26%

Bearish Bullish

68%32%

News